Research LettersUse of pentoxifylline in membranous nephropathy
References (3)
- et al.
Adhesion molecules and urinary tumor necrosis factor-α in idiopathic membranous glomerulonephritis
Kidney Int
(1998)
Cited by (59)
Inflammation in Chronic Kidney Disease
2019, Chronic Renal DiseaseTherapeutic targets for treating fibrotic kidney diseases
2015, Translational ResearchCitation Excerpt :In a pilot double-blind, randomized, placebo-controlled clinical trial of 40 patients with CKD, pentoxifylline slowed the eGFR decline, but had no significant effect on proteinuria after 1 year of treatment.138 However, in 2 separate pilot studies (one including 10 patients with idiopathic membranous nephropathy139 and the second including 40 patients with type 2 diabetes140), pentoxifylline was shown to decrease proteinuria, and a prospective randomized placebo-controlled study is being conducted in South Korea to evaluate the effects of pentoxifylline on proteinuria in type 2 diabetic patients (clinicaltrials.gov identifier: NCT01382303). A phase 4 multicenter, randomized, double-blind, placebo-controlled clinical trial is currently ongoing to investigate the renoprotective efficacy of combined pentoxifylline and ARB valsartan compared with placebo and valsartan in 700 patients with CKD stages 3 and 4 (clinicaltrials.gov identifier: NCT01377285).
Inflammation in Chronic Kidney Disease
2015, Chronic Renal DiseaseCarboplatin-induced Fanconi-like syndrome in rats: Amelioration by pentoxifylline
2014, Environmental Toxicology and PharmacologyCitation Excerpt :However, it can be observed upon retrospection that these effects might be due to PTX-mediated increase in renal blood flow through its hemorheologic action which is mediated through non-specific phosphodiesterase inhibition. Additionally, the renoprotective ability of PTX and its anti-TNFα action might also play a positive role in this protective effect (Ducloux et al., 2001; Navarro et al., 1999). It also has anti-fibrotic actions which are mediated through its ability to reduce lymphocyte profliferation and production of extracellular matrix proteins (Strutz et al., 2000).
Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line
2012, Biomedicine and PharmacotherapyCitation Excerpt :This facilitates an easy translation of the compound in a clinical set up as the pharmacokinetics and side effects of the drug are known. PTX, a phosphodiesterase inhibitor has been widely used in dilated cardiomyopathy [21] and nephropathy [22]. Due to its lower toxicity it is presently in focus as an anticancer and antimetastatic agent.
Off the Beaten Renin-Angiotensin-Aldosterone System Pathway: New Perspectives on Antiproteinuric Therapy
2011, Advances in Chronic Kidney DiseaseCitation Excerpt :The authors concluded that quality of the existing studies was low. In a pilot study of 10 patients with membranous nephropathy, pentoxifylline reduced mean proteinuria from 11 g/d to 2 g/d, with nearly 90% drop in serum and urine TNF levels.63 In a randomized trial (lacking a placebo and thus lacking blinding) that involved 85 subjects with moderate-to-severe CKD, pentoxifylline group had a median 28% reduction in proteinuria, whereas the control group had a median 14% increase.64